StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)

Stock analysts at StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the stock.

TherapeuticsMD Stock Performance

TherapeuticsMD stock opened at $1.58 on Tuesday. TherapeuticsMD has a 1 year low of $1.43 and a 1 year high of $3.07. The firm has a 50 day moving average price of $1.70 and a 200 day moving average price of $1.84.

TherapeuticsMD (NASDAQ:TXMD) last issued its earnings results on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter. The company had revenue of $0.23 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in TherapeuticsMD stock. Prosperity Consulting Group LLC purchased a new position in TherapeuticsMD, Inc. (NASDAQ:TXMD) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned approximately 0.21% of TherapeuticsMD as of its most recent filing with the Securities & Exchange Commission. 30.74% of the stock is currently owned by hedge funds and other institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.